Q3 2024 CV Sciences Inc Earnings Call Transcript
Key Points
- CV Sciences Inc (CVSI) maintained a healthy gross margin of 46% during Q3 2024, which compares favorably with prior quarters.
- The company launched a new line of cannabinoid-free supplements, +PlusHLTH, which includes innovative products like CLARITY, PEACE, and RESHAPE.
- CV Sciences Inc (CVSI) completed strategic acquisitions, including Elevated Softgels and Cultured Foods, to increase capability, scale, and profitability.
- The company maintained its number 1 position in the natural product retail channel and increased market share in the B2B channel.
- CV Sciences Inc (CVSI) is actively involved in shaping the regulatory environment at both federal and state levels, aiming to advance the industry responsibly.
- Q3 2024 revenue was $3.9 million, slightly down from $4.1 million in Q3 2023, indicating a decline in unit sales and average sales prices.
- The emergency order in California restricting certain hemp products negatively impacted Q3 revenues.
- The company reported an operating loss of $0.3 million for Q3 2024, although improved from the previous year.
- CV Sciences Inc (CVSI) continues to face challenges in the fragmented and competitive CBD market.
- The company anticipates modest cash usage in the near future until synergies from acquisitions are realized and positive cash flow is generated in 2025.
Greetings, and welcome to the CV Sciences third quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Brendan Hawkins, Investor Relations. Thank you, sir. You may begin.
Thank you, and good morning, everyone. With us today with prepared remarks are CV Sciences' Chief Executive Officer, Joseph Dowling; and Joerg Grasser, Chief Financial Officer. After the prepared remarks, we will take questions from the analyst community.
I'd like to remind you that during this call, management's prepared remarks may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by CV Sciences at this time. When used in this call, the words anticipate, should, could, estimate, intend, expect, believe, potential, will, project, and similar expressions as they relate to CV Sciences are as such forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
